Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017:2017:7687098.
doi: 10.1155/2017/7687098. Epub 2017 Dec 28.

Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis

Ting Zhai  1 , Shi-Zhen Li  1 , Xin-Tong Fan  2 , Zhao Tian  2 , Xiao-Qing Lu  3 , Jing Dong  4   5
Affiliations
Meta-Analysis

Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis

Ting Zhai et al. J Diabetes Res. 2017.

Abstract

The role of nesfatin-1 in glucose homeostasis has been investigated previously. However, although numerous studies have examined the relationships between circulating nesfatin-1 levels and type 2 diabetes, the conclusions are contradictory. We aimed to probe the relationship between circulating nesfatin-1 levels and type 2 diabetes by meta-analysis. Seven studies including 328 type 2 diabetes patients and 294 control subjects were included. Although there was no obvious difference in circulating nesfatin-1 levels between patients with type 2 diabetes and the control group (MD = -0.04; 95% CI = -0.32 to -0.23), subgroup analysis showed higher nesfatin-1 levels in newly diagnosed type 2 diabetes patients (MD = 0.59; 95% CI = 0.45 to 0.74) and significantly lower nesfatin-1 levels in type 2 diabetes patients receiving antidiabetic treatment (MD = -0.26; 95% CI = -0.33 to -0.20). In conclusion, the analysis supports a relationship between circulating nesfatin-1 levels and type 2 diabetes, where newly diagnosed type 2 diabetes was associated with an elevated Nesfatin-1 level, and type 2 diabetes patients receiving antidiabetic treatment showed lower circulating nesfatin-1 levels.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart for selection of eligible studies.
Figure 2
Figure 2
Forest plot of circulating nesfatin-1 levels and type 2 diabetes. (a) Overall meta-analysis of circulating nesfatin-1 levels in type 2 diabetes (random effects model). (b) Subgroup analysis of nesfatin-1 in newly diagnosed type 2 diabetes or antidiabetic treatment (random effects model). (c) Subgroup analysis of type 2 diabetes with treatment from China (random effects model).
See this image and copyright information in PMC

References

    1. Ohi S., Shimizu H., Satoh T., et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443(7112):709–712. doi: 10.1038/nature05162. - DOI - PubMed
    1. Su Y., Zhang J., Tang Y., Bi F., Liu J. N. The novel function of nesfatin-1: anti-hyperglycemia. Biochemical and Biophysical Research Communications. 2009;391(1):1039–1042. doi: 10.1016/j.bbrc.2009.12.014. - DOI - PubMed
    1. Yang M., Zhang Z., Wang C., et al. Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance. Diabetes. 2012;61(8):1959–1968. doi: 10.2337/db11-1755. - DOI - PMC - PubMed
    1. Nakata M., Manaka K., Yamamoto S., Mori M., Yada T. Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet β-cells. Endocrine Journal. 2011;58(4):305–313. doi: 10.1507/endocrj.K11E-056. - DOI - PubMed
    1. Pan W., Hsuchou H., Kastin A. J. Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides. 2007;28(11):2223–2228. doi: 10.1016/j.peptides.2007.09.005. - DOI - PubMed

MeSH terms

LinkOut - more resources